ACTINOGEN MEDICAL LIMITED - Announcements

Market Cap $74.46M Add to my watchlist

Healthcare Biotechnology

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is... Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ACW	Proposed issue of securities - ACW		03/05/24	32.34KB	Share
ACW	Actinogen announces capital raising of up to $8.9 million	PRICE SENSITIVE	03/05/24	2.68MB	Share
ACW	Trading Halt	PRICE SENSITIVE	01/05/24	333.62KB	Share
ACW	ACW March 2024 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/04/24	592.09KB	Share
ACW	ACW completes cognition & depression phase 2 trial enrolment	PRICE SENSITIVE	22/04/24	244.8KB	Share
ACW	First patient treated in ACW XanaMIA ph 2b Alzheimers trial	PRICE SENSITIVE	15/04/24	238.21KB	Share
ACW	Notification of cessation of securities - ACW		15/04/24	12.73KB	Share
ACW	Appendix 3Y-Mr Malcolm McComas		05/04/24	193.86KB	Share
ACW	Notification of cessation of securities - ACW		05/04/24	12.77KB	Share
ACW	Application for quotation of securities - ACW		03/04/24	17.11KB	Share
ACW	ACW corporate presentation revised licensing slide		25/03/24	356.48KB	Share
ACW	Notification of buy-back - ACW		20/03/24	12.67KB	Share
ACW	Actinogen corporate presentation March 2024		20/03/24	3.22MB	Share
ACW	Application for quotation of securities - ACW		07/03/24	15.49KB	Share
ACW	ACW XanaCIDD depression trial enters final enrolment phase		07/03/24	241.33KB	Share
ACW	Actinogen CMO presents at ADPD 2024 conference		06/03/24	474.43KB	Share
ACW	Actinogen HY2024 financial results two key phase 2 trial	PRICE SENSITIVE	26/02/24	256.58KB	Share
ACW	Actinogen HY2024 financial report and Appendix 4D	PRICE SENSITIVE	26/02/24	2.75MB	Share
ACW	Application for quotation of securities - ACW		21/02/24	17.95KB	Share
ACW	Response to ASX Aware Query	PRICE SENSITIVE	20/02/24	934.62KB	Share
ACW	Application for quotation of securities - ACW		16/02/24	17.94KB	Share
ACW	Actinogen awarded UK Innovation Passport for Xanamem	PRICE SENSITIVE	15/02/24	242.2KB	Share
ACW	Application for quotation of securities - ACW		09/02/24	17.51KB	Share
ACW	Notification of cessation of securities - ACW		01/02/24	21.59KB	Share
ACW	ACW December 2023 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/01/24	510KB	Share
ACW	Positive Xanamem brain PET study peer-reviewed publication		24/01/24	274.99KB	Share
ACW	ACW CEO & CMO present at Sachs Neuroscience Innovation Forum		08/01/24	1.97MB	Share
ACW	First site activated in ACW XanaMIA Phase 2b AD trial		20/12/23	241.49KB	Share
ACW	Notification of cessation of securities - ACW		13/12/23	21.6KB	Share
ACW	Appendix 3Ys x 5		01/12/23	284.49KB	Share
ACW	Application for quotation of securities - ACW		01/12/23	30.38KB	Share
ACW	Appendix 3Y-Dr George Morstyn		28/11/23	194.64KB	Share
ACW	Appendix 3Y-Dr Geoff Brooke		28/11/23	194.89KB	Share
ACW	Notification of cessation of securities - ACW		28/11/23	21.61KB	Share
ACW	Actinogen receives $4.8 million R&D tax incentive rebate	PRICE SENSITIVE	28/11/23	224.74KB	Share
ACW	ACW XanaCIDD trial enrolment exceeds 50 percent		28/11/23	221.05KB	Share
ACW	Amended Constitution		17/11/23	420.34KB	Share
ACW	Results of AGM		17/11/23	237.83KB	Share
ACW	Actinogen 2023 AGM - Chairs address and CEOs presentation		17/11/23	2.48MB	Share
ACW	ACW CEO presents at Bell Potter Healthcare Conference 2023		15/11/23	3.15MB	Share
ACW	Application for quotation of securities - ACW		08/11/23	26.71KB	Share
ACW	Actinogen appoints William Souter as new CFO		08/11/23	239.79KB	Share
ACW	Amendment to Actinogen 2023 AGM resolutions 6 to 10		27/10/23	212.49KB	Share
ACW	ACW CMO presents academic poster at CTAD 2023 conference		25/10/23	592.86KB	Share
ACW	ACW CEO presentation for meetings at BIO Investor Forum USA		18/10/23	3.33MB	Share
ACW	Actinogen September quarterly activity report & Appendix 4C	PRICE SENSITIVE	16/10/23	511.35KB	Share
ACW	Annual Report to Shareholders		13/10/23	4.19MB	Share
ACW	Letter to Shareholders, Notice of AGM & Proxy Form		13/10/23	714.25KB	Share
ACW	Notification of cessation of securities - ACW		11/10/23	21.52KB	Share
ACW	ACW CEO presents to Dementia Trials Australia conference		06/10/23	1.69MB	Share
ACW	ACW presents to the Asian Society Against Dementia congress		29/09/23	1.54MB	Share
ACW	Change in substantial holding		27/09/23	166.64KB	Share
ACW	Notification of buy-back - ACW		27/09/23	21.78KB	Share
ACW	Date of AGM and Closing Date for Director Nominations		27/09/23	174.05KB	Share
ACW	Actinogen enhances XanaMIA Phase 2b Alzheimers trial	PRICE SENSITIVE	26/09/23	219.7KB	Share
ACW	Change in substantial holding		20/09/23	166.67KB	Share
ACW	Notification regarding unquoted securities - ACW		15/09/23	27.49KB	Share
ACW	Application for quotation of securities - ACW		15/09/23	24.81KB	Share
ACW	Appendix 3Y-Mr Malcolm McComas		12/09/23	195.82KB	Share
ACW	Appendix 3Y-Dr George Morstyn		12/09/23	195.15KB	Share
ACW	Appendix 3Y-Dr Steven Gourlay		12/09/23	194.14KB	Share
ACW	Appendix 3Y-Dr Geoffrey Brooke		12/09/23	241.05KB	Share
ACW	Notification regarding unquoted securities - ACW		11/09/23	23.88KB	Share
ACW	Application for quotation of securities - ACW		11/09/23	24.91KB	Share
ACW	Actinogen closes successful $10 million rights issue offer	PRICE SENSITIVE	07/09/23	218.02KB	Share
ACW	Prof Paul Maruff & Dr Dana Hilt webinar & slide deck		31/08/23	1.37MB	Share
ACW	Actinogen FY2023 results, following the science	PRICE SENSITIVE	30/08/23	269.85KB	Share
ACW	Appendix 4G		30/08/23	286.39KB	Share
ACW	Corporate Governance Statement		30/08/23	372.33KB	Share
ACW	ACW Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	30/08/23	4.11MB	Share
ACW	ACW secures further $0.5m rights issue shortfall commitment	PRICE SENSITIVE	30/08/23	224.98KB	Share
ACW	ACW appoints company for rights issue shareholder contact		30/08/23	269.47KB	Share
ACW	Prof Paul Maruff on neuroscience drug development & Xanamem		29/08/23	217.16KB	Share
ACW	Letter to Ineligible Shareholders		17/08/23	213.3KB	Share
ACW	Letter to Eligible Shareholders - Rights Issue Opens		17/08/23	270.52KB	Share
ACW	ACW secures shortfall commitments of $4.56m for rights issue	PRICE SENSITIVE	15/08/23	222.88KB	Share
ACW	Entitlement Offer Prospectus	PRICE SENSITIVE	08/08/23	1.26MB	Share
ACW	Proposed issue of securities - ACW		02/08/23	33.77KB	Share
ACW	Actinogen announces $10 million rights offer	PRICE SENSITIVE	02/08/23	259.74KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	31/07/23	330.43KB	Share
ACW	Trading Halt	PRICE SENSITIVE	31/07/23	642.62KB	Share
ACW	ACW CEO presents at Bioshares Biotech Summit		25/07/23	2.7MB	Share
ACW	Actinogen CMO presents academic poster to AAIC Conference		17/07/23	622.82KB	Share
ACW	ACW CEO presentation on emerging oral Alzheimers therapies		21/06/23	1.49MB	Share
ACW	ACW CEO & CMO present at BIO International Convention		05/06/23	1.52MB	Share
ACW	ACW AD trial amendment and Clinical Science Forum slides	PRICE SENSITIVE	24/05/23	1.69MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	24/04/23	325.71KB	Share
ACW	Actinogen CMO presents at ADPD 2023 conference		31/03/23	1.38MB	Share
ACW	Application for quotation of securities - ACW		20/03/23	26.61KB	Share
ACW	Appendix 3X - Dr Nicki Vasquez		01/03/23	149.99KB	Share
ACW	ACW appoints Dr Nicki Vasquez as a Non-Executive Director		01/03/23	244KB	Share
ACW	Actinogen CEO presents to Spark Plus Biotech conference		24/02/23	1.71MB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	22/02/23	1.33MB	Share
ACW	Actinogen appoints Dr Dana Hilt as Chief Medical Officer		01/02/23	240.38KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	30/01/23	389.51KB	Share
ACW	ACW CEO presentation Sachs Neuroscience and JPM week		09/01/23	1.54MB	Share
ACW	Letter to Shareholders - CEO 2022 Review & Outlook		22/12/22	394.21KB	Share
ACW	FDA agrees to six-month Phase 2b Alzheimers Disease Trial	PRICE SENSITIVE	22/12/22	235.52KB	Share
ACW	Cleansing Notice		09/12/22	205.68KB	Share
ACW	Application for quotation of securities - ACW		09/12/22	24.71KB	Share

ACW Proposed issue of securities - ACW
03/05/24		32.34KB	Share
ACW Actinogen announces capital raising of up to $8.9 million
03/05/24	PRICE SENSITIVE	2.68MB	Share
ACW Trading Halt
01/05/24	PRICE SENSITIVE	333.62KB	Share
ACW ACW March 2024 quarterly activity report & Appendix 4C
30/04/24	PRICE SENSITIVE	592.09KB	Share
ACW ACW completes cognition & depression phase 2 trial enrolment
22/04/24	PRICE SENSITIVE	244.8KB	Share
ACW First patient treated in ACW XanaMIA ph 2b Alzheimers trial
15/04/24	PRICE SENSITIVE	238.21KB	Share
ACW Notification of cessation of securities - ACW
15/04/24		12.73KB	Share
ACW Appendix 3Y-Mr Malcolm McComas
05/04/24		193.86KB	Share
ACW Notification of cessation of securities - ACW
05/04/24		12.77KB	Share
ACW Application for quotation of securities - ACW
03/04/24		17.11KB	Share
ACW ACW corporate presentation revised licensing slide
25/03/24		356.48KB	Share
ACW Notification of buy-back - ACW
20/03/24		12.67KB	Share
ACW Actinogen corporate presentation March 2024
20/03/24		3.22MB	Share
ACW Application for quotation of securities - ACW
07/03/24		15.49KB	Share
ACW ACW XanaCIDD depression trial enters final enrolment phase
07/03/24		241.33KB	Share
ACW Actinogen CMO presents at ADPD 2024 conference
06/03/24		474.43KB	Share
ACW Actinogen HY2024 financial results two key phase 2 trial
26/02/24	PRICE SENSITIVE	256.58KB	Share
ACW Actinogen HY2024 financial report and Appendix 4D
26/02/24	PRICE SENSITIVE	2.75MB	Share
ACW Application for quotation of securities - ACW
21/02/24		17.95KB	Share
ACW Response to ASX Aware Query
20/02/24	PRICE SENSITIVE	934.62KB	Share
ACW Application for quotation of securities - ACW
16/02/24		17.94KB	Share
ACW Actinogen awarded UK Innovation Passport for Xanamem
15/02/24	PRICE SENSITIVE	242.2KB	Share
ACW Application for quotation of securities - ACW
09/02/24		17.51KB	Share
ACW Notification of cessation of securities - ACW
01/02/24		21.59KB	Share
ACW ACW December 2023 quarterly activity report & Appendix 4C
30/01/24	PRICE SENSITIVE	510KB	Share
ACW Positive Xanamem brain PET study peer-reviewed publication
24/01/24		274.99KB	Share
ACW ACW CEO & CMO present at Sachs Neuroscience Innovation Forum
08/01/24		1.97MB	Share
ACW First site activated in ACW XanaMIA Phase 2b AD trial
20/12/23		241.49KB	Share
ACW Notification of cessation of securities - ACW
13/12/23		21.6KB	Share
ACW Appendix 3Ys x 5
01/12/23		284.49KB	Share
ACW Application for quotation of securities - ACW
01/12/23		30.38KB	Share
ACW Appendix 3Y-Dr George Morstyn
28/11/23		194.64KB	Share
ACW Appendix 3Y-Dr Geoff Brooke
28/11/23		194.89KB	Share
ACW Notification of cessation of securities - ACW
28/11/23		21.61KB	Share
ACW Actinogen receives $4.8 million R&D tax incentive rebate
28/11/23	PRICE SENSITIVE	224.74KB	Share
ACW ACW XanaCIDD trial enrolment exceeds 50 percent
28/11/23		221.05KB	Share
ACW Amended Constitution
17/11/23		420.34KB	Share
ACW Results of AGM
17/11/23		237.83KB	Share
ACW Actinogen 2023 AGM - Chairs address and CEOs presentation
17/11/23		2.48MB	Share
ACW ACW CEO presents at Bell Potter Healthcare Conference 2023
15/11/23		3.15MB	Share
ACW Application for quotation of securities - ACW
08/11/23		26.71KB	Share
ACW Actinogen appoints William Souter as new CFO
08/11/23		239.79KB	Share
ACW Amendment to Actinogen 2023 AGM resolutions 6 to 10
27/10/23		212.49KB	Share
ACW ACW CMO presents academic poster at CTAD 2023 conference
25/10/23		592.86KB	Share
ACW ACW CEO presentation for meetings at BIO Investor Forum USA
18/10/23		3.33MB	Share
ACW Actinogen September quarterly activity report & Appendix 4C
16/10/23	PRICE SENSITIVE	511.35KB	Share
ACW Annual Report to Shareholders
13/10/23		4.19MB	Share
ACW Letter to Shareholders, Notice of AGM & Proxy Form
13/10/23		714.25KB	Share
ACW Notification of cessation of securities - ACW
11/10/23		21.52KB	Share
ACW ACW CEO presents to Dementia Trials Australia conference
06/10/23		1.69MB	Share
ACW ACW presents to the Asian Society Against Dementia congress
29/09/23		1.54MB	Share
ACW Change in substantial holding
27/09/23		166.64KB	Share
ACW Notification of buy-back - ACW
27/09/23		21.78KB	Share
ACW Date of AGM and Closing Date for Director Nominations
27/09/23		174.05KB	Share
ACW Actinogen enhances XanaMIA Phase 2b Alzheimers trial
26/09/23	PRICE SENSITIVE	219.7KB	Share
ACW Change in substantial holding
20/09/23		166.67KB	Share
ACW Notification regarding unquoted securities - ACW
15/09/23		27.49KB	Share
ACW Application for quotation of securities - ACW
15/09/23		24.81KB	Share
ACW Appendix 3Y-Mr Malcolm McComas
12/09/23		195.82KB	Share
ACW Appendix 3Y-Dr George Morstyn
12/09/23		195.15KB	Share
ACW Appendix 3Y-Dr Steven Gourlay
12/09/23		194.14KB	Share
ACW Appendix 3Y-Dr Geoffrey Brooke
12/09/23		241.05KB	Share
ACW Notification regarding unquoted securities - ACW
11/09/23		23.88KB	Share
ACW Application for quotation of securities - ACW
11/09/23		24.91KB	Share
ACW Actinogen closes successful $10 million rights issue offer
07/09/23	PRICE SENSITIVE	218.02KB	Share
ACW Prof Paul Maruff & Dr Dana Hilt webinar & slide deck
31/08/23		1.37MB	Share
ACW Actinogen FY2023 results, following the science
30/08/23	PRICE SENSITIVE	269.85KB	Share
ACW Appendix 4G
30/08/23		286.39KB	Share
ACW Corporate Governance Statement
30/08/23		372.33KB	Share
ACW ACW Appendix 4E and 2023 Annual Report
30/08/23	PRICE SENSITIVE	4.11MB	Share
ACW ACW secures further $0.5m rights issue shortfall commitment
30/08/23	PRICE SENSITIVE	224.98KB	Share
ACW ACW appoints company for rights issue shareholder contact
30/08/23		269.47KB	Share
ACW Prof Paul Maruff on neuroscience drug development & Xanamem
29/08/23		217.16KB	Share
ACW Letter to Ineligible Shareholders
17/08/23		213.3KB	Share
ACW Letter to Eligible Shareholders - Rights Issue Opens
17/08/23		270.52KB	Share
ACW ACW secures shortfall commitments of $4.56m for rights issue
15/08/23	PRICE SENSITIVE	222.88KB	Share
ACW Entitlement Offer Prospectus
08/08/23	PRICE SENSITIVE	1.26MB	Share
ACW Proposed issue of securities - ACW
02/08/23		33.77KB	Share
ACW Actinogen announces $10 million rights offer
02/08/23	PRICE SENSITIVE	259.74KB	Share
ACW Quarterly Activity Report & Appendix 4C
31/07/23	PRICE SENSITIVE	330.43KB	Share
ACW Trading Halt
31/07/23	PRICE SENSITIVE	642.62KB	Share
ACW ACW CEO presents at Bioshares Biotech Summit
25/07/23		2.7MB	Share
ACW Actinogen CMO presents academic poster to AAIC Conference
17/07/23		622.82KB	Share
ACW ACW CEO presentation on emerging oral Alzheimers therapies
21/06/23		1.49MB	Share
ACW ACW CEO & CMO present at BIO International Convention
05/06/23		1.52MB	Share
ACW ACW AD trial amendment and Clinical Science Forum slides
24/05/23	PRICE SENSITIVE	1.69MB	Share
ACW Quarterly Activity Report & Appendix 4C
24/04/23	PRICE SENSITIVE	325.71KB	Share
ACW Actinogen CMO presents at ADPD 2023 conference
31/03/23		1.38MB	Share
ACW Application for quotation of securities - ACW
20/03/23		26.61KB	Share
ACW Appendix 3X - Dr Nicki Vasquez
01/03/23		149.99KB	Share
ACW ACW appoints Dr Nicki Vasquez as a Non-Executive Director
01/03/23		244KB	Share
ACW Actinogen CEO presents to Spark Plus Biotech conference
24/02/23		1.71MB	Share
ACW Appendix 4D & Half-Year Financial Statements
22/02/23	PRICE SENSITIVE	1.33MB	Share
ACW Actinogen appoints Dr Dana Hilt as Chief Medical Officer
01/02/23		240.38KB	Share
ACW Quarterly Activity Report & Appendix 4C
30/01/23	PRICE SENSITIVE	389.51KB	Share
ACW ACW CEO presentation Sachs Neuroscience and JPM week
09/01/23		1.54MB	Share
ACW Letter to Shareholders - CEO 2022 Review & Outlook
22/12/22		394.21KB	Share
ACW FDA agrees to six-month Phase 2b Alzheimers Disease Trial
22/12/22	PRICE SENSITIVE	235.52KB	Share
ACW Cleansing Notice
09/12/22		205.68KB	Share
ACW Application for quotation of securities - ACW
09/12/22		24.71KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 3.2¢		Change -0.006(15.8%)		Mkt cap ! $74.46M

Open	High	Low	Value	Volume
3.0¢	3.4¢	2.9¢	$186.2K	6.157M

Buyers (Bids)

No.	Vol.	Price($)
2	189149	3.2¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	621429	4

View Market Depth

No.	Vol.	Price($)
3	1189823	0.031
2	320000	0.030
3	704790	0.029
10	3577903	0.028
4	175148	0.027

Price($)	Vol.	No.
0.034	121429	3
0.035	800000	2
0.036	27800	1
0.038	406078	4
0.039	39666	2

Last trade - 15.52pm 03/05/2024 (20 minute delay)


Last 3.2¢		Change -0.006 ( 11.1 %)
Open	High	Low	Volume
3.0¢	3.4¢	2.9¢	3278602
Last updated 15.52pm 03/05/2024 ?

ACW (ASX) Chart

ACTINOGEN MEDICAL LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available